Baxter, Cerus Enter $120 Mil. Platelet Market With EU Intercept Approval
This article was originally published in The Gray Sheet
Executive Summary
Baxter and Cerus plan to launch the first pathogen inactivation system for blood platelets by October, pending widespread blood bank validations and CE mark of a companion device
You may also be interested in...
Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data
Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete
Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data
Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete
Vitex, Baxter Target West Nile Virus With Red Blood Cell Screening Systems
West Nile Virus is one of the pathogens for which Baxter/Cerus and Vitex plan to market the red blood cell inactivation systems Intercept and Inactine, respectively